

Financial Tear Sheet

Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

Stock Information

BCLI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Price	\$4.09
Change (%)	▼ 0.1 (2.39%)
Volume	32,143
52 Week Low	\$2.06
Market Cap	\$78,658,504
Rolling EPS	-0.27
PE Ratio	0
Shares Outstanding	18,763,956
Data as of 09/22/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

August 14, 2017

BRAINSTORM ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS

August 10, 2017

BRAINSTORM TO HOST SECOND-QUARTER 2017 EARNINGS TELECONFERENCE AND PROVIDE IMPORTANT CORPORATE UPDATES, ON WEDNESDAY, AUGUST 16

August 7, 2017

BRAINSTORM SUPPORTS COMMITMENT TO ALS PATIENT COMMUNITY WITH APPOINTMENT OF A VICE PRESIDENT OF PATIENT ADVOCACY AND GOVERNMENT AFFAIRS

SEC Filings

Filing Date	Form
09/14/17	DEF 14A
08/31/17	4
08/23/17	4
08/14/17	10-Q

Upcoming Events

There are currently no events scheduled.

Primary IR Contact

Michael Rice
LifeSci Advisors LLC
E-mail: mrice@lifesciadvisors.com